An overview of once‐weekly glucagon‐like peptide‐1 receptor agonists—available efficacy and safety data and perspectives for the future
Sten Madsbad(Hvidovre Hospital), Jens J. Holst(University of Copenhagen), Meena Asmar(University of Copenhagen), Signe S. Torekov(University of Copenhagen), Urd Kielgast(Hvidovre Hospital), Carolyn F. Deacon(University of Copenhagen)
Cited by 201
Related Papers
3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial
|The Lancet|2017|843
Low Physical Activity Accentuates the Effect of the <i>FTO</i> rs9939609 Polymorphism on Body Fat Accumulation
|Diabetes|2007|476
Impact of postprandial glycaemia on health and prevention of disease
|Obesity Reviews|2012|470
Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined
|New England Journal of Medicine|2021|469
Incretins, insulin secretion and Type 2 diabetes mellitus
|Diabetologia|2004|438